Show notes
In this episode of Derms and Conditions, host Dr James Q. Del Rosso returns from the 2025Winter Clinical Dermatology Conference – Miami® with a deep dive into some of the standoutposters presented at the meeting.Dr Del Rosso begins the review with new insights on topical clascoterone 1% cream and itsimpact on the skin barrier, tolerability, and sebum reduction. He explores recent studiesshowing that clascoterone does not compromise the permeability barrier or increasetransepidermal water loss—key considerations for its use alongside other acne treatments likebenzoyl peroxide and topical retinoids.The analysis shifts to a comparative study on a triple combination acne therapy featuringclindamycin 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1%, which demonstrated superiorefficacy over dual-combination formulations. Dr Del Rosso breaks down early activity data,inflammatory and non-inflammatory lesion reductions, and how polymeric emulsiontechnology enhances both efficacy and tolerability.He also highlights new data on topical ruflomilast for atopic dermatitis in younger patients(ages 2-5) and explores the recent FDA approval of tapinarof 1% cream for atopic dermatitisdown to age two. Posters on itch and sleep improvements in pediatric patients, as well asefficacy in skin of color, provide valuable clinical insights.Tune in for this rapid-fire breakdown of key posters, packed with data-driven takeaways toenhance your dermatology practice.



